Nutriband (NASDAQ:NTRB) Stock Price Breaks Above 50-Day Moving Average – Should You Sell?

Nutriband Inc. (NASDAQ:NTRB) shares crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $6.25 and traded as high as $6.41. Nutriband shares last traded at $6.4750, with a volume of 71,074 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NTRB. Wall Street Zen raised Nutriband to a “hold” rating in a report on Saturday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Nutriband in a research report on Monday, September 28th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce”.

Nutriband Stock Up 8.8%

The firm’s 50-day moving average is $6.25 and its 200-day moving average is $4.35. The company has a market capitalization of $78.71 million, a PE ratio of -12.22 and a beta of 1.92.

Nutriband (NASDAQ:NTRB) last released its quarterly earnings results on Friday, September 4th. The company reported ($0.07) earnings per share for the quarter. Nutriband had a negative net margin of 430.35% and a negative return on equity of 109.07%. The firm had revenue of $0.44 million for the quarter.

About Nutriband

Nutriband Inc is a medical technology company focused on developing and commercializing transdermal and topical products. The company’s platform is designed to deliver active pharmaceutical ingredients through the skin, with applications in prescription medicines, over-the-counter products, consumer health, and veterinary care.

Nutriband also provides contract manufacturing and product development services for transdermal patches and related products. Its offerings include adhesive patches and other topical delivery formats, as well as formulation, manufacturing, packaging, and regulatory support for customers developing transdermal therapies.

The company’s proprietary AVERSA technology is intended to incorporate abuse-deterrent and tamper-resistant features into transdermal drug-delivery systems.